Efficacy and safety of adjunctive lacosamide for the treatment of partial-onset seizures in Chinese and Japanese adults: A randomized, double-blind, placebo-controlled study

@article{Hong2016EfficacyAS,
  title={Efficacy and safety of adjunctive lacosamide for the treatment of partial-onset seizures in Chinese and Japanese adults: A randomized, double-blind, placebo-controlled study},
  author={Zhen Hong and Yushi Inoue and Weiping Liao and Hongmei Meng and Xuefeng Wang and Wenmin Wang and Liemin Zhou and Liming Zhang and Xinlu Du and Frank Tennigkeit},
  journal={Epilepsy Research},
  year={2016},
  volume={127},
  pages={267-275}
}
OBJECTIVE To evaluate the efficacy and safety of adjunctive lacosamide treatment in Chinese and Japanese adults with uncontrolled focal (partial-onset) seizures (POS), with or without secondary generalization. METHODS A 24-week, randomized, double-blind, placebo-controlled study (EP0008; NCT01710657) was conducted in patients (aged 16-70 years) with uncontrolled POS and taking 1-3 concomitant antiepileptic drugs from 72 sites across China and Japan. Following an 8-week Baseline period… Expand
Efficacy and tolerability of adjunctive lacosamide in pediatric patients with focal seizures
TLDR
Adjunctive lacosamide was efficacious in reducing seizure frequency and generally well tolerated in patients (age ≥4–<17 years) with focal seizures and provides Class I evidence that for children and adolescents with uncontrolled focal seizures, adjunctive Lacosamide reduces seizure frequency. Expand
Efficacy upon 12-weeks after achievement of maximal dose and tolerability of lacosamide as an adjunctive therapy in epilepsy: Real world clinical experience
TLDR
This study has shown LCM to have comparable efficacy and tolerability in post-marketing experience when compared with the landmark randomized controlled trials. Expand
Tolerability of lacosamide rapid dose titration: A randomized, multicenter, prospective, open-label study
  • Y. Shin, J. Moon, +15 authors Sang Kun Lee
  • Medicine
  • Epilepsy & Behavior
  • 2021
TLDR
Rapid titration protocols for lacosamide were not associated with an increased risk of adverse events compared to the conventional weekly titration protocol, suggesting Uptitration of lacosamia at shorter intervals to an effective target dosage may be feasible in appropriate clinical situations. Expand
Lacosamide: A Review in Focal-Onset Seizures in Patients with Epilepsy
TLDR
Oral lacosamide was generally well tolerated over the short- and longer-term when administered as adjunctive therapy, a conversion to monotherapy agent and monotherapy in adults and adolescents and when administer as adj unctive therapy in children aged ≥ 4 years. Expand
Influence of adjunctive lacosamide in patients with seizures: a systematic review and meta-analysis
TLDR
Compared to placebo, adjunctive lacosamide treatment resulted in a significantly improved 50% responder rate and seizure freedom, but with increased dizziness, nausea, vomiting, diplopia, treatment-emergent adverse events and serious adverse events. Expand
Newer antiepileptic drugs compared to levetiracetam as adjunctive treatments for uncontrolled focal epilepsy: An indirect comparison
TLDR
Indirect comparisons suggested that ESL, LAC and BRV were not inferior to Levetiracetam in efficacy and may have a possible worse tolerability profile compared to LEV at high dose. Expand
Indirect comparison of third-generation antiepileptic drugs as adjunctive treatment for uncontrolled focal epilepsy
TLDR
There were no significant differences in efficacy between third generation AEDs in uncontrolled focal epilepsy and BRV may have the best tolerability profile, according to a meta-analysis conducted through an online database search. Expand
The adverse-effect profile of lacosamide
TLDR
The review showed that lacosamide is safe and effective in antiepileptic treatment, and its common side effects are dizziness, headache, drowsiness, diplopia, and cardiovascular abnormalities. Expand
Is Therapeutic Drug Monitoring of Lacosamide Needed in Patients with Seizures and Epilepsy?
TLDR
While it is not practical to utilize TDM for all patients, TDM may be useful in patients taking enzyme-inducer AEDs, in patients with decreased renal function or on dialysis, and older adults. Expand
Value of Perampanel as Adjunctive Treatment for Partial-Onset Seizures in Epilepsy: Cost-Effectiveness and Budget Impact Analysis
TLDR
Perampanel (8 or 4 mg/day) is of relatively high value as an add-on therapeutic regimen for partial-onset seizures in China because of its dominate advantage of cost-effectiveness over LCM and acceptable budget impact. Expand
...
1
2
...

References

SHOWING 1-10 OF 21 REFERENCES
Safety and tolerability of lacosamide as adjunctive therapy for adults with partial-onset seizures: Analysis of data pooled from three randomized, double-blind, placebo-controlled clinical trials
TLDR
The safety and tolerability profile of adjunctive lacosamide in this detailed evaluation was similar to that observed in the individual double-blind trials. Expand
Safety and efficacy of adjunctive lacosamide among patients with partial-onset seizures in a long-term open-label extension trial of up to 8years
TLDR
Exposure to lacosamide for up to 8 years was generally well tolerated, with a safety profile similar to previous double-blind trials, and efficacy was maintained. Expand
Examining the Clinical Utility of Lacosamide
TLDR
All three dosages of Lacosamide (200, 400 and 600 mg/day) showed a significant improvement compared with placebo for median percent seizure reduction, and the onset of efficacy relative to placebo was evident by the first week of treatment with lacosamide. Expand
Pharmacokinetics of Lacosamide in Healthy Korean Male Volunteers
TLDR
There were no other ethnic differences in the PK profile of lacosamide between Koreans and Caucasians based on the population PK analysis, except for the demographic differences. Expand
Long‐term safety and efficacy in patients with uncontrolled partial‐onset seizures treated with adjunctive lacosamide: Results from a phase III open‐label extension trial
TLDR
To evaluate the long‐term safety and efficacy of lacosamide as adjunctive therapy in patients with uncontrolled partial‐onset seizures taking one to three concomitant antiepileptic drugs (AEDs) in open‐label extension trial SP756 (NCT00522275). Expand
Advances in epilepsy treatment: lacosamide pharmacokinetic profile
TLDR
The favorable and predictable pharmacokinetics profile and bioequivalence of LCM formulations, coupled with the low potential for clinically relevant pharmacokinetic drug–drug interactions, make LCM an easy‐to‐use adjunctive treatment for the management of patients with focal epilepsy. Expand
Adjunctive lacosamide for partial‐onset seizures: Efficacy and safety results from a randomized controlled trial
TLDR
To evaluate the efficacy and safety of lacosamide when added to one to three concomitant antiepileptic drugs (AEDs) in patients with uncontrolled partial‐onset seizures. Expand
Lacosamide as adjunctive therapy for partial‐onset seizures: A randomized controlled trial
TLDR
The objective is to evaluate the efficacy and safety of lacosamide as adjunctive treatment in patients with uncontrolled partial‐onset seizures taking one to three concomitant antiepileptic drugs (AEDs). Expand
Efficacy and Safety of Oral Lacosamide as Adjunctive Therapy in Adults with Partial‐Onset Seizures
Summary:  Purpose: To evaluate the efficacy and safety of lacosamide when added to 1 or 2 antiepileptic drugs (AEDs) in adults with uncontrolled partial‐onset seizures, and assess plasmaExpand
Long‐term adjunctive lacosamide treatment in patients with partial‐onset seizures
To evaluate long‐term (up to 5.5 years) safety, seizure reduction, and maintenance of efficacy of the antiepileptic drug (AED) lacosamide as adjunctive treatment in an open‐label extension trialExpand
...
1
2
3
...